{"prompt": "['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'SAE review', 'X', 'X', 'Section 5.1', 'Overall Design', 'Original text:', 'A study schematic is shown in Figure 1. This is a parallel group study. Following', 'screening and assessment of rescue medication use via a daily diary over study days - -7 to', '1, participants will be randomized (1:1) to receive either danirixin 35mg tablets or', 'placebo. Study treatment will be administered twice daily for 52 weeks [Figure 1].', 'There will be no pre-specified interim analysis for this study. An interim analysis may be', 'performed if it is determined that the enrolment is slow enough to allow it to be', 'informative. There will be no IDMC for this study. An internal safety review team will', 'meet approximately every 3 months (or as needed based on emerging data) to review', 'available safety information.', 'Figure 1', 'Study Schematic', '52 weeks', 'Placebo (n=50)', '7 days', 'Follow-up2', 'Screening\u00b9', 'R', 'Danirixin, 35mg', '(n=50)', '1 If changes to medication are required, consent must be signed prior to any changes being made and may', 'occur prior to the Screening Visit', '2 Follow-up visit to occur within 28days of last dose of study medication', 'Amended text:', 'A study schematic is shown in Figure 1. This is a parallel group study. Following', 'screening and assessment of rescue medication use via a daily diary over study days -28', 'to 1, participants will be randomized (1:1) to receive either danirixin 35mg tablets or', 'placebo. Study treatment will be administered twice daily for 52 weeks [Figure 1].', 'There will be no pre-specified interim analysis for this study. An interim analysis may be', 'performed if it is determined that the enrolment is slow enough to allow it to be', 'informative. There will be no IDMC for this study. An internal safety review team will', '84']['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'meet approximately every 3 months (or as needed based on emerging data) to review', 'available safety information.', 'Figure 1', 'Study Schematic', '52 weeks', 'Up to 28', 'Placebo (n=50)', 'days', 'Follow-up2', 'Screening', 'R', 'Danirixin, 35mg', '(n=50)', '1 If changes to medication are required, consent must be signed prior to any changes being made and may', 'occur prior to the Screening Visit', '2', 'Follow-up visit to occur within 28days of last dose of study medication', 'Section 6.1', 'Inclusion Criteria', 'Original text:', '2', 'Male or female', 'Male participants:', 'A male participant must agree to use contraception as detailed in Appendix 5 of this', 'protocol during the treatment period and for at least 60 hours after the last dose of', 'study treatment, corresponding to approximately 6 half-lives (which is the time', 'needed to eliminate any teratogenic study treatment) and to refrain from donating', 'sperm during this period.', 'Female participants:', 'A female participant is eligible to participate if she is not pregnant (see Section 12.5;', 'Appendix 5), not breastfeeding, and at least one of the following conditions applies:', 'i.', 'Not a woman of childbearing potential (WOCBP) as defined in Section 12.5', '(Appendix 5)', 'OR', '85']['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'ii. A WOCBP who agrees to follow the contraceptive guidance in Section 12.5', '(Appendix 5) during the treatment period and for at least 60 hours after the', 'last dose of study treatment.', 'Revised text:', '3', 'Male or female', 'Male participants:', 'A male participant must agree to use contraception as detailed in Appendix 5 of this', 'protocol during the treatment period and for at least 60 hours after the last dose of', 'study treatment, corresponding to approximately 6 half-lives (which is the time', 'needed to eliminate any teratogenic study treatment) and to refrain from donating', 'sperm during this period.', 'Female participants:', 'A female participant is eligible to participate if she is not a woman of childbearing', 'potential (WOCBP) as defined in Section 12.5 (Appendix 5)', 'Section 12.2 Appendix 2:', 'Original text:', 'Table 7', 'Protocol-Required Safety Laboratory Assessments', 'Laboratory', 'Parameters', 'Assessments', 'Hematology', 'Platelet Count', 'RBC Indices:', 'WBC count with', 'RBC Count', 'MCV', 'Differential:', 'Hemoglobin', 'MCH', 'Neutrophils', 'Hematocrit', 'MCHC', 'Lymphocytes', 'Monocytes', 'Eosinophils', 'Basophils', 'Clinical', 'BUN', 'Potassium', 'Aspartate', 'Total and direct', 'Chemistry1', 'Chloride', 'Aminotransferase', 'bilirubin', 'Bicarbonate', '(AST)/Serum', 'Glutamic-', 'Oxaloacetic', 'Transaminase', '(SGOT)', 'Creatinine', 'Sodium', 'Alanine', 'Total Protein', 'Aminotransferase', '(ALT)/ Serum', 'Glutamic-Pyruvic', 'Transaminase', '(SGPT)', 'Glucose (fasting', 'Calcium', 'Alkaline', '86']\n\n###\n\n", "completion": "END"}